CapsoVision's third quarter split the story in two. The company delivered on nearly every regulatory, clinical and financing milestone it had promised, but the commercial engine that is supposed to fund those ambitions barely moved. The net loss of $0.15 per share matched consensus exactly and improved 11.8% from a year ago. Revenue of $3.57 million missed the $3.8 million consensus by 6.1% and grew only 0.8% year over year. That is a sharp deceleration from roughly 10% growth in the second quarter and about 15% for fiscal 2025, and it is the central tension of the report. CapsoVision is asking investors to look past a stalled core business toward catalysts that will not fully show up in the numbers until 2027.
The quality of the EPS result deserves scrutiny. The net loss narrowed to $7.3 million from $7.9 million, almost entirely because research and development spending fell to $4.8 million from $6.1 million as the CapsoCam Colon pivotal study wound down. Selling and marketing rose to $2.1 million from $1.8 million, and general and administrative expense rose to $2.3 million from $2.1 million. Per-share comparisons also benefited from a weighted share count of about 50.6 million, up from 46.2 million a year earlier. Gross margin moved the wrong way. It fell to 49% from 51% in the second quarter and 54% a year ago. The company attributed the decline to higher flash memory costs, a one-time inventory obsolescence charge and higher stock-based compensation. Gross profit therefore declined even though revenue edged higher. The narrower loss reflects lower spending, not operating leverage.
The call made the volume problem explicit. Capsule shipments were 8,464, up only about 1.5% year over year and down from 8,845 in the second quarter. In the prior quarter, shipments had grown 13%. Management cited a competitive U.S. pricing environment as weighing on small-bowel results. That sits awkwardly beside the release's statement that average selling price was stable year over year. The more plausible reading is that CapsoVision held price and paid for it in volume, particularly against rivals that already market FDA-cleared AI reading tools, a risk the company flags in its filings. There were offsetting signs of reach. CapsoVision added 34 new accounts, including nine hospital systems, and cumulative patients imaged rose to more than 184,000 from 176,000 in the second quarter. Those additions have not yet translated into revenue momentum.
The forward calendar is where management's more confident tone comes from. AI Highlights won FDA clearance on September 25 and launched in the U.S. on November 2. That met the end-of-third-quarter target set on the prior call, after an earlier slip from mid-year. Management expects the tool to accelerate CapsoCam Plus growth, but the full impact is now framed for 2027, which pushes back the payoff. The bigger swing factor is CapsoCam Colon. Enrollment and data collection for the second-generation study are complete, topline data are expected next month, and the 510(k) submission remains on track for year-end 2026, a timeline that had already shifted from the third quarter. The pancreatic UGI study is expanding beyond two community sites toward more than a dozen larger centers, and an esophageal varices trial is planned for the second half of 2027. Reaffirmed guidance for second-half revenue above first-half revenue is a low bar. First-half revenue was about $6.4 million, and the third quarter alone delivered $3.57 million.
The balance sheet was refilled, but at shareholders' expense. Cash rose to $21.8 million from $9.1 million at the end of the second quarter, helped by an $18 million registered direct offering from existing shareholders and $1.7 million in at-the-market sales. Shares outstanding climbed to 53.6 million from 46.9 million at the start of the year. Operating cash burn was $21.5 million over nine months. At that pace, the new cushion covers only about three quarters of burn unless clinical spending falls as management expects, so further dilution remains a live risk.
The market was skeptical heading into the print. Investor sentiment stood firmly negative at -0.52. Shares at $6.27 were down 3.5% from the opening price after the August report and sat about 1.5% below the 200-day moving average. The stock had rallied to an inter-earnings high of $7.23 on October 29, likely on anticipation of the AI clearance and launch, but had already given back 13.3% of that move before the report. It remained 9% above the August low of $5.75. Trend readings lean negative, with AVWAP weak even as sequential growth registers positively.
The bottom line is that CapsoVision executed on its pipeline and funding but not on its commercial growth. An in-line loss built on lower R&D, a revenue miss, near-zero shipment growth and shrinking margins leave bears with legitimate ammunition. Bulls are now relying on colon topline data next month and a 2027 AI-driven reacceleration, and both will need to deliver before the dilution math improves.